Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Alpha-1 MP in Japanese AATD Patients
NCT02870348Phase 2Completed
- Sponsor
- Grifols
- Start
- Jul 2016
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Started Jul 2016; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT02870348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870348.